Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786645 | 0.89 | AAK1 (0.53) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL551648 | 0.89 | HDAC1 (0.50) | AAK1CYP17A1HDAC1HSP90AA1HSP90AB1 | |
| SCHEMBL30485007 | 0.89 | HDAC1 (0.50) | AAK1CYP17A1HDAC1HSP90AA1HSP90AB1 | |
| SCHEMBL5869025 | 0.88 | AAK1 (0.47) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL24233399 | 0.88 | AAK1 (0.52) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL5868802 | 0.88 | ABCB1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL5869075 | 0.88 | AAK1 (0.52) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL1753916 | 0.88 | ABCB1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| Ammonia Solution, Strong SCHEMBL21835798 | 0.86 | ABCB1 (0.53) | AAK1CYP17A1MAP4K4ABCB1ABCC1 | |
| SCHEMBL25216132 | 0.86 | CYP17A1 (0.54) | AAK1CYP17A1MAP4K4ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | AAK1 1593/4885CYP17A1 1449/4885MAP4K4 4064/4885 |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | AAK1 2510/4885CYP17A1 1294/4885MAP4K4 1369/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | AAK1 2207/4885CYP17A1 1907/4885MAP4K4 3537/4885 |
| US-20060148791-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | AAK1 2207/4885CYP17A1 1907/4885MAP4K4 3537/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | AAK1 3018/4885CYP17A1 657/4885MAP4K4 1521/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | AAK1 3018/4885CYP17A1 657/4885MAP4K4 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.